Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
The price of Novavax, Inc (NASDAQ: NVAX) closed at $9.5 in the last session, up 9.57% from day before closing price of $8.67. In other words, the price has increased by $9.57 from its previous closing price. On the day, 8.91 million shares were traded. NVAX stock price reached its highest trading level at $9.6299 during the session, while it also had its lowest trading level at $8.63.
Ratios:
We take a closer look at NVAX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 2.34 and its Current Ratio is at 2.36. In the meantime, Its Debt-to-Equity ratio is 6.07 whereas as Long-Term Debt/Eq ratio is at 5.93.
On August 20, 2025, BofA Securities Downgraded its rating to Underperform which previously was Neutral but kept the price unchanged to $7.
On June 17, 2025, Citigroup started tracking the stock assigning a Sell rating and target price of $6.Citigroup initiated its Sell rating on June 17, 2025, with a $6 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on May 19 ’25 when YOUNG JAMES F bought 10,000 shares for $7.59 per share.
YOUNG JAMES F bought 4,000 shares of NVAX for $24,406 on Apr 14 ’25. On Dec 13 ’24, another insider, King Rachel K., who serves as the Director of the company, sold 4,150 shares for $9.02 each. As a result, the insider received 37,435 and left with 14,770 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NVAX now has a Market Capitalization of 1543005696 and an Enterprise Value of 1159191680. As of this moment, Novavax,’s Price-to-Earnings (P/E) ratio for their current fiscal year is 4.21. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.11. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.43 while its Price-to-Book (P/B) ratio in mrq is 40.94. Its current Enterprise Value per Revenue stands at 1.075 whereas that against EBITDA is 2.845.
Stock Price History:
The Beta on a monthly basis for NVAX is 2.75, which has changed by -0.39875174 over the last 52 weeks, in comparison to a change of 0.17342639 over the same period for the S&P500. Over the past 52 weeks, NVAX has reached a high of $15.22, while it has fallen to a 52-week low of $5.01. The 50-Day Moving Average of the stock is 17.69%, while the 200-Day Moving Average is calculated to be 24.48%.
Shares Statistics:
According to the various share statistics, NVAX traded on average about 6.22M shares per day over the past 3-months and 3796720 shares per day over the past 10 days. A total of 162.16M shares are outstanding, with a floating share count of 148.06M. Insiders hold about 8.84% of the company’s shares, while institutions hold 58.82% stake in the company. Shares short for NVAX as of 1757894400 were 44723391 with a Short Ratio of 7.19, compared to 1755216000 on 38100228. Therefore, it implies a Short% of Shares Outstanding of 44723391 and a Short% of Float of 27.639999999999997.
Earnings Estimates
At present, 5.0 analysts are actively evaluating the performance of Novavax, Inc (NVAX) in the stock market.The consensus estimate for the next quarter is -$0.42, with high estimates of $0.23 and low estimates of -$1.51.
Analysts are recommending an EPS of between $3.26 and $1.45 for the fiscal current year, implying an average EPS of $2.62. EPS for the following year is -$0.0, with 7.0 analysts recommending between $2.9 and -$1.3.
Revenue Estimates
According to 6 analysts,. The current quarter’s revenue is expected to be $55.63M. It ranges from a high estimate of $89.8M to a low estimate of $32.55M. As of. The current estimate, Novavax, Inc’s year-ago sales were $84.51MFor the next quarter, 6 analysts are estimating revenue of $128.06M. There is a high estimate of $264.9M for the next quarter, whereas the lowest estimate is $60.94M.
A total of 8 analysts have provided revenue estimates for NVAX’s current fiscal year. The highest revenue estimate was $1.21B, while the lowest revenue estimate was $1B, resulting in an average revenue estimate of $1.07B. In the same quarter a year ago, actual revenue was $682.16MBased on 8 analysts’ estimates, the company’s revenue will be $450.24M in the next fiscal year. The high estimate is $1.07B and the low estimate is $271.14M.
